
    
      Exploratory hypothesis 1: There will be a statistically significant difference in the
      percentage of responders in the two treatment groups; response rates will be significantly
      higher for the ziprasidone monotherapy compared to the placebo group.

      Exploratory hypothesis 2: The change in 6-VAS-D scores during the trial will be highly
      correlated to the change in HAM-D-17 and QIDS-SR during the trial.
    
  